Medical cannabis billing is mostly about knowing what insurance won’t pay for and keeping it off the claim. Health plans don’t cover marijuana itself or the visits whose only purpose is a state cannabis certification, so most certification clinics run as self-pay practices. Many of those same providers also treat chronic pain, anxiety, sleep problems, or cancer symptoms, and that medical care can be billed and credentialed like any other practice, as long as the two sides are kept apart.
Key Takeaways
- Medicare, Medicaid, and commercial plans don’t cover state-legal medical marijuana, and the April 2026 move to Schedule III didn’t change that.
- Visits held only to certify a patient for a state cannabis program are generally self-pay, while separate evaluation and treatment of a medical condition can be billed when the record supports it.
- Self-pay patients are entitled to a good faith estimate under the No Surprises Act before a scheduled service.
- FDA-approved cannabinoid drugs such as dronabinol, nabilone, and Epidiolex are covered under pharmacy benefits, usually with prior authorization.
- A Medicare CBD pilot launched in 2026 runs only inside selected CMS models, and the products aren’t billed to Medicare.
What Changed with Schedule III
In April 2026, the DEA moved two narrow categories of marijuana from Schedule I to Schedule III. One is marijuana in an FDA-approved drug product, and the other is marijuana covered by a state medical marijuana license. Adult-use marijuana and everything else stayed in Schedule I, and a broader hearing on moving the rest of marijuana to Schedule III was held in June and July 2026, with no final decision yet. The DEA’s rescheduling page tracks each step.
For billing, the change matters less than the headlines suggest. State-licensed medical marijuana is still not an FDA-approved drug, so it still isn’t something Medicare, Medicaid, or commercial plans cover. Clinicians in state programs still certify or recommend rather than prescribe, and dispensaries, not medical practices, carry the new DEA registration requirements.
Certification Visits and Billable Care
A visit held only to evaluate a patient for a state cannabis card is not a covered service, and billing it to insurance under an office visit code invites denials and audits. Most practices set a flat self-pay fee for initial certifications and renewals and collect it at the time of service.
The picture changes when the same provider is also treating the patient’s underlying condition. A pain, oncology, neurology, or behavioral health visit that addresses diagnosis, medications, and a treatment plan can be billed under the usual E/M codes, with diagnoses for the conditions treated, when the note shows that work. The safest setup keeps certification and medical care in separate encounters or clearly separated documentation, so a payer never pays for the certification by accident. Our pain management and behavioral health pages cover the coding for two of the most common overlapping specialties, and our CPT code category index covers the rest.
Self-pay patients have their own protections. Under the No Surprises Act, uninsured patients and insured patients who choose not to use coverage must get a good faith estimate of expected charges for a scheduled service, and they can dispute a final bill that comes in substantially higher.
Covered Cannabinoid Drugs and the Medicare CBD Pilot
A handful of cannabinoid medicines are FDA-approved and covered like other prescriptions. Dronabinol and nabilone treat chemotherapy-related nausea and, for dronabinol, AIDS-related weight loss, and Epidiolex treats seizures in several rare epilepsy syndromes. They’re billed through the patient’s pharmacy benefit, and most plans require prior authorization showing the approved indication and, for nausea, that other treatments were tried first.
In 2026 CMS also started a CBD pilot for Medicare patients, limited to providers in selected models such as ACO REACH and the Enhancing Oncology Model. Participating providers can give patients up to $500 a year of qualifying hemp-derived CBD products as part of their care, but the products aren’t billed to Medicare and aren’t a standard Medicare benefit. The pilot faces a pending court challenge, and federal hemp rules taking effect in November 2026 could narrow which products qualify.
Credentialing for Cannabis Medicine Practices
Payers don’t credential anyone for cannabis medicine, because they don’t cover it. A provider who also bills covered care goes through standard credentialing with each plan, with the usual license, board certification, DEA registration, malpractice, and work history checks, and enrolls in Medicare through PECOS if the practice sees Medicare patients.
The state cannabis program is a separate registration. Most states require certifying clinicians to register with the program, complete any required training, and renew on the state’s schedule, and some limit which license types can certify. Practices should track those renewals alongside payer recredentialing, since a lapsed state registration stops certifications even when payer enrollment is current. Practices that also offer acupuncture, massage, or other integrative services can see our holistic therapy page.
Medical Cannabis Billing FAQ
Does insurance cover medical marijuana?
No. Medicare, Medicaid, and commercial health plans don’t cover state-legal medical marijuana, because it isn’t an FDA-approved drug. Patients pay for cannabis products at the dispensary.
Did the 2026 move to Schedule III change insurance coverage?
No. The April 2026 order moved state-licensed medical marijuana and FDA-approved marijuana products to Schedule III, but state-licensed products still aren’t FDA-approved drugs, so plans still don’t cover them.
Can a medical cannabis certification visit be billed to insurance?
Generally not. A visit held only to certify a patient for a state program is a self-pay service. Separate evaluation and treatment of a covered medical condition can be billed under the usual E/M codes when the record documents that work.
Which cannabis-based medicines does insurance cover?
FDA-approved cannabinoid drugs such as dronabinol, nabilone, and Epidiolex are covered under pharmacy benefits for their approved uses. Most plans require prior authorization.
What is the Medicare CBD pilot?
A 2026 CMS initiative that lets providers in selected models, including ACO REACH and the Enhancing Oncology Model, give Medicare patients up to $500 a year of qualifying hemp-derived CBD. The products aren’t billed to Medicare.
Do self-pay cannabis patients need a good faith estimate?
Yes. Under the No Surprises Act, uninsured patients and patients who choose not to use insurance must receive a good faith estimate before a scheduled service.
Medwave for Cannabis Medicine Practices
The billing risk in a cannabis practice usually sits in the overlap, with a certification visit that slips onto a claim or covered care that never gets billed. Medwave helps practices draw that line in their scheduling and documentation, then bills the covered side through our medical billing team, which holds a 98% clean claim rate.
For providers adding insurance-based care, our medical credentialing team handles payer enrollment and averages 85 days to approval, while keeping track of state program registrations so nothing lapses. Our answer to whether we support cannabis medicine billing covers the kinds of practices we work with.
If your cannabis practice is thinking about billing insurance for the medical care it already provides, tell us what you offer and we’ll sort out what’s billable.